BioMS Medical to participate in panel session at Bio International Convention 2009
- “BioMS/Eli Lilly – Dissecting a Billion Dollar Collaboration” -
Toronto Stock Exchange Symbol: MS
Also participating in the panel session will be Mr.
WHEN: Thursday May 21st at 8:00am (Eastern Time) WHERE: Room B316, Georgia World Congress Center, Atlanta, Georgia BioMS Medical will also provide a corporate presentation at the Business Forum at 9:40am (Eastern Time) on Wednesday May 20th. About BIO International Convention ---------------------------------- The BIO International Convention, hosted by the Biotechnology Industry Organization, is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on major trends affecting the industry. For more information visit http://convention.bio.org/. About BioMS Medical Corp. -------------------------
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in
This press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE BioMS Medical Corp.